Last reviewed · How we verify
SARS-CoV-2 variant mRNA vaccine low dose
SARS-CoV-2 variant mRNA vaccine low dose is a Biologic drug developed by AIM Vaccine Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | SARS-CoV-2 variant mRNA vaccine low dose |
|---|---|
| Sponsor | AIM Vaccine Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People (NA)
- A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China (NA)
- Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SARS-CoV-2 variant mRNA vaccine low dose CI brief — competitive landscape report
- SARS-CoV-2 variant mRNA vaccine low dose updates RSS · CI watch RSS
- AIM Vaccine Co., Ltd. portfolio CI
Frequently asked questions about SARS-CoV-2 variant mRNA vaccine low dose
What is SARS-CoV-2 variant mRNA vaccine low dose?
SARS-CoV-2 variant mRNA vaccine low dose is a Biologic drug developed by AIM Vaccine Co., Ltd..
Who makes SARS-CoV-2 variant mRNA vaccine low dose?
SARS-CoV-2 variant mRNA vaccine low dose is developed by AIM Vaccine Co., Ltd. (see full AIM Vaccine Co., Ltd. pipeline at /company/aim-vaccine-co-ltd).
What development phase is SARS-CoV-2 variant mRNA vaccine low dose in?
SARS-CoV-2 variant mRNA vaccine low dose is in Phase 1.